breast cancer

News

Radiology technician examens mammography test on location

EU regulators reject Puma's Nerlynx breast cancer drug

European regulators have rejected Puma’s breast cancer drug Nerlynx (neratinib) – diverging from the FDA, which opted to grant the drug a licence last year.

News

ESMO: Trodelvy's overall survival benefit revealed

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury i

News

End of the line for Sanofi's SERD amcenestrant as it fails f...

Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.

News

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medic

News

Survival data firms up Trodelvy prospects in new breast canc...

In the space of a couple of months, Gilead Sciences' Trodelvy impact on overall survival (OS) in the TROPICs-02 trial in advanced breast cancer has gone from a trend to a statistically sign

News

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients.

EU regulators reject Puma's Nerlynx breast cancer drug

ESMO: Trodelvy's overall survival benefit revealed

End of the line for Sanofi's SERD amcenestrant as it fails f...

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

Survival data firms up Trodelvy prospects in new breast canc...

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

breast cancer

Editor's Picks